ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

NVO Novo Nordisk

125.40
0.81 (0.65%)
Pre Market
Last Updated: 10:28:07
Delayed by 15 minutes
Share Name Share Symbol Market Type
Novo Nordisk NYSE:NVO NYSE Common Stock
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  0.81 0.65% 125.40 10,826 10:28:07

Specialized Disclosure Report (sd)

22/05/2019 2:29pm

Edgar (US Regulatory)


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

 

 

FORM SD

 

 

 

Specialized Disclosure Report

 

  NOVO NORDISK A/S  
(Exact name of the registrant as specified in its charter)
 
The Kingdom of Denmark 333-82318 N/A
(State or other jurisdiction of
Incorporation or organization)
(Commission
File Number)
(IRS Employer
Identification No.)
     
Novo Allé, DK-2880 Bagsværd, Denmark   N/A
(Address of principal executive offices)   (Zip code)
     
Karsten Munk Knudsen +45 4444 8888
(Name and telephone number, including area code, of the
person to contact in connection with this report.)
       
Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:
 
  X     Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2018.

 

 

 

Section 1 - Conflict Minerals Disclosure

 

Items 1.01 and 1.02 Conflict Minerals Disclosure and Report, Exhibit

 

Conflict Minerals Disclosure

 

A copy of Novo Nordisk A/S’s Conflict Minerals Report for the year ended December 31, 2018 is provided as Exhibit 1.01 hereto and is publicly available at: https://www.novonordisk.com/sustainable-business/performance-on-tbl/more-about-how-we-work-and-report/transparency-disclosures.html

 

Section 2 – Exhibits

 

Item 2.01 Exhibits

 

Exhibit 1.01 – Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form.

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.

 

Date: May 22, 2019 NOVO NORDISK A/S
   
   
  By: /s/ Karsten Munk Knudsen
  Name: Karsten Munk Knudsen
  Title: Executive Vice President & Chief Financial Officer

 

 

 

 

1 Year Novo Nordisk Chart

1 Year Novo Nordisk Chart

1 Month Novo Nordisk Chart

1 Month Novo Nordisk Chart

Your Recent History

Delayed Upgrade Clock